Viviane Maimoni Goncalves

Dr. Viviane Maimoni Goncalves

Instituto Butantan, Laboratório de Desenvolvimento de Vacinas
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Vaccine
Verified
Journal Article
Closed access
YLYing-Jie Lu
Ying-Jie Lu
LLLuciana Leite
Luciana Leite
Viviane Maimoni GoncalvesViviane Maimoni Goncalves
Viviane Maimoni Goncalves
WDWaldely de Oliveira Dias
Waldely de Oliveira Dias
CLCelia Liberman
Celia Liberman
RMRick Malley
Rick Malley

1 June 2020 in Biotechnology Reports
Verified
Journal Article
Open access
VCValdemir M. Cardoso
Valdemir M. Cardoso
GCGilson Campani
Gilson Campani
MSMaurício P. Santos
Maurício P. Santos
GSGabriel G. Silva
Gabriel G. Silva
MPManuella C. Pires
Manuella C. Pires
TZTeresa Cristina Zangirolami
Teresa Cristina Zangirolami
The impact of cultivation strategy on the cost of recombinant protein production is crucial for defining cost-effective bioreactor operation conditions. This paper presents a methodology to estimate and compare cost impacts related to utilities as well as medium composition, using simple design equations and accessible data. Data from batch bioreactor cultures were used as case study involving the production of pneumococcal surface protein A, a soluble recombinant protein, employing E. coli BL21(DE3). Cultivation strategies and corresponding process costs covered a wide range of operational conditions, including different media, inducers, and temperatures. The core expenses were related to the medium and cooling. When the price of peptone was above the threshold value of US$ 30/kg, defined medium became the best choice. IPTG and temperatures around 32 °C led to shorter cultures and lower PspA4Pro production costs. The procedure offers a simple, accessible theoretical tool to identify cost-effective production strategies using bioreactors.

31 December 2019 in AMB Express
Verified
Journal Article
Open access
PDF file
AKAlex Issamu Kanno
Alex Issamu Kanno
LLLuciana C. C. Leite
Luciana C. C. Leite
LPLennon Ramos Pereira
Lennon Ramos Pereira
MRMonica Josiane Rodrigues-Jesus
Monica Josiane Rodrigues-Jesus
RARobert Andreata-Santos
Robert Andreata-Santos
Viviane Maimoni GoncalvesViviane Maimoni Goncalves
Viviane Maimoni Goncalves
Diagnosing Zika virus (ZIKV) infections has been challenging due to the cross-reactivity of induced antibodies with other flavivirus. The concomitant occurrence of ZIKV and Dengue virus (DENV) in endemic regions requires diagnostic tools with the ability to distinguish these two viral infections. Recent studies demonstrated that immunoassays using the C-terminal fragment of ZIKV NS1 antigen (ΔNS1) can be used to discriminate ZIKV from DENV infections. In order to be used in serological tests, the expression/solubility of ΔNS1 and growth of recombinant E. coli strain were optimized by Response Surface Methodology. Temperature, time and IPTG concentration were evaluated. According to the model, the best condition determined in small scale cultures was 21 °C for 20 h with 0.7 mM of IPTG, which predicted 7.5 g/L of biomass and 962 mg/L of ΔNS1. These conditions were validated and used in a 6-L batch in the bioreactor, which produced 6.4 g/L of biomass and 500 mg/L of ΔNS1 in 12 h of induction. The serological ELISA test performed with purified ΔNS1 showed low cross-reactivity with antibodies from DENV-infected human subjects. Denaturation of ΔNS1 decreased the detection of anti-ZIKV antibodies, thus indicating the contribution of conformational epitopes and confirming the importance of properly folded ΔNS1 for the specificity of the serological analyses. Obtaining high yields of soluble ΔNS1 supports the viability of an effective serologic diagnostic test capable of differentiating ZIKV from other flavivirus infections.

1 November 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Nitesh KundaNitesh Kunda
Nitesh Kunda
IAIman Alfagih
Iman Alfagih
EMEliane Miyaji
Eliane Miyaji
DFDouglas B. Figueiredo
Douglas B. Figueiredo
Viviane Maimoni GoncalvesViviane Maimoni Goncalves
Viviane Maimoni Goncalves
Imran SaleemImran Saleem
Imran Saleem

23 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TRTasson da Costa Rodrigues
Tasson da Costa Rodrigues
MOMaria Leonor S Oliveira
Maria Leonor S Oliveira
ASAlessandra Soares-Schanoski
Alessandra Soares-Schanoski
SCStefanni L Chavez-Rico
Stefanni L Chavez-Rico
DFDouglas B Figueiredo
Douglas B Figueiredo
EMEliane Miyaji
Eliane Miyaji
Burden of pneumonia caused by Streptococcus pneumoniae remains high despite the availability of conjugate vaccines. Mucosal immunization targeting the lungs is an attractive alternative for the induction of local immune responses to improve protection against pneumonia. Our group had previously described the development of poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) polymeric nanoparticles (NPs) adsorbed with Pneumococcal surface protein A from clade 4 (PspA4Pro) within L-leucine microcarriers (nanocomposite microparticles—NCMPs) for mucosal delivery targeting the lungs (NP/NCMP PspA4Pro). NP/NCMP PspA4Pro was now used for immunization of mice. Inoculation of this formulation induced anti-PspA4Pro IgG antibodies in serum and lungs. Analysis of binding of serum IgG to intact bacteria showed efficient binding to bacteria expressing PspA from clades 3, 4 and 5 (family 2), but no binding to bacteria expressing PspA from clades 1 and 2 (family 1) was observed. Both mucosal immunization with NP/NCMP PspA4Pro and subcutaneous injection of the protein elicited partial protection against intranasal lethal pneumococcal challenge with a serotype 3 strain expressing PspA from clade 5 (PspA5). Although similar survival levels were observed for mucosal immunization with NP/NCMP PspA4Pro and subcutaneous immunization with purified protein, NP/NCMP PspA4Pro induced earlier control of the infection. Conversely, neither immunization with NP/NCMP PspA4Pro nor subcutaneous immunization with purified protein reduced bacterial burden in the lungs after challenge with a serotype 19F strain expressing PspA from clade 1 (PspA1). Mucosal immunization with NP/NCMP PspA4Pro targeting the lungs is thus able to induce local and systemic antibodies, conferring protection only against a strain expressing PspA from the homologous family 2.

1 June 2003 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
PDF file
Viviane Maimoni GoncalvesViviane Maimoni Goncalves
Viviane Maimoni Goncalves
Viviane Maimoni GoncalvesViviane Maimoni Goncalves
Viviane Maimoni Goncalves
MTMickie Takagi
Mickie Takagi
RLRodrigo B. Lima
Rodrigo B. Lima
HMHugo Massaldi
Hugo Massaldi
MTMartha M. Tanizaki
Martha M. Tanizaki